4.5 Article

SUMOylation of Tr2 orphan receptor involves Pml and fine-tunes Oct4 expression in stem cells

Journal

NATURE STRUCTURAL & MOLECULAR BIOLOGY
Volume 14, Issue 1, Pages 68-75

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nsmb1185

Keywords

-

Funding

  1. NIDA NIH HHS [K02 DA13926, DA11190] Funding Source: Medline
  2. NIDDK NIH HHS [DK60521, DK54733] Funding Source: Medline
  3. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054733, R01DK060521] Funding Source: NIH RePORTER
  4. NATIONAL INSTITUTE ON DRUG ABUSE [K02DA013926, R01DA011190] Funding Source: NIH RePORTER

Ask authors/readers for more resources

The Tr2 orphan nuclear receptor can be SUMOylated, resulting in the replacement of coregulators recruited to the regulatory region of its endogenous target gene, Oct4. UnSUMOylated Tr2 activates Oct4, enhancing embryonal carcinoma-cell proliferation, and is localized to the promyelocytic leukemia ( Pml) nuclear bodies. When its abundance is elevated, Tr2 is SUMOylated at Lys238 and seems to be released from the nuclear bodies to act as a repressor. SUMOylation of Tr2 induces an exchange of its coregulators: corepressor Rip140 replaces coactivator Pcaf, which switches Tr2 from an activator to a repressor. This involves dynamic partitioning of Tr2 into Pml-containing and Pml-free pools. These results support a model where SUMOylation-dependent partitioning and differential coregulator recruitment contribute to the maintenance of a homeostatic supply of activating, as opposed to repressive, Tr2, thus fine-tuning Oct4 expression and regulating stem-cell proliferation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available